Document:

exv10w55

Exhibit 10.55

Execution Version

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

Amendment To The License Agreement

This Amendment, effective the 12th day of February, 2009, (“Amendment Date”) is by and between
Idera Pharmaceuticals, Inc., having a place of business located at 167 Sidney Street, Cambridge,
Massachusetts 02139 (“Idera”) and Merck KGaA, a general partnership limited by shares organized
under German law having a place of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany
(“Merck”). Idera and Merck may be referred to collectively as “Parties.”

Background

The Parties entered into a License Agreement dated 18 December 2007 (“License Agreement”), which
sets forth certain terms and conditions for the Parties to research, develop and commercialize
immune modulatory oligonucleotides in the field of cancer.

The Parties now desire to amend the License Agreement to allow Idera to continue to act as the
sponsor (as such term is defined in 21 CFR § 312.3(b), hereinafter “Sponsor”) of certain clinical
trials until such time as Merck has filed an Investigational New Drug application with the US Food
and Drug Administration and assumes the Sponsor role under the Merck IND.

Now, Therefore, the Parties hereby agree as follows:

1. Section 1.17, definition of “Development Costs” is hereby amended and restated in its entirety
as follows:

     “Development Costs” means those Out-of-Pocket Expenses incurred by Licensor after the
Effective Date that are directly and solely attributable to the achievement of work or activities
performed by or on behalf of Licensor after the Effective Date toward the completion of the
On-Going Trials or the Future Trials.

2. Section 3.4, of the License Agreement, Licensor Support in the Development, is hereby amended
and restated in its entirety as follows:

3.4(a). Licensor Support in the Development. For a period of [**] starting from Effective
Date, Licensor shall make its employees that are knowledgeable on the Compound or Follow-On
Compound, its properties and functions, reasonably available to Merck, at Licensor’s
facilities, for scientific and technical explanations, advice and support, that may
reasonably be required by Merck, relating to the Development and registration of the
Compound, Follow-On Compound and the Licensed Products (the “Development Support”). The
Development Support shall be provided by Licensor [**] during such first [**] following the
Effective Date. Thereafter, during the remaining [**] period, Merck shall reimburse
Licensor for Licensor’s reasonable Out-of-Pocket Expenses incurred in providing the
Development Support should Merck require any of such Development Support, subject however to
Licensor providing Merck with documented evidence of such Out-of-Pocket Expenses having been
incurred.

					
	 	 	 	 	 
	License Agreement Amendment
	 	Page 1 of 10
	 	Confidential

 

 

Execution Version

3.4(b). Licensor Sponsorship and Conduct of Clinical Trials. Notwithstanding Section 2.3
and 3.4(a), during the Interim Period Licensor agrees to remain the Sponsor for the On-Going
Trials and for additional Clinical Trials that the Parties agree to conduct during the
Interim Period, including the study in [**] (“Future Trials” and together with the On-Going
Trials, collectively, the “TLR9 Agonist Trials”). For purposes of this Agreement, the
“Interim Period” means that period of time commencing on the Effective Date and ending on
the date that is the earlier of (i) the date on which the FDA has approved the IND submitted
by Merck for conducting clinical trials with Licensor’s TLR9 agonists (the “Merck TLR9
Agonists IND”) and Merck has assumed the role of Sponsor for all on-going TLR9 Agonist
Trials or (b) the date that is twenty-four (24) months from the Effective Date. The following provisions shall
apply during the Interim Period in connection with the conduct of the TLR9 Agonist Trials:

	 	(1)	 	Such trials shall be conducted under Licensor’s IND Application
Number[**] or IND Application Number [**].
	 
	 	(2)	 	Licensor’s acts shall be in compliance with Section 3.2.
	 
	 	(3)	 	The Parties shall establish an agreement for each TLR9 Agonist
Trial that sets forth each Party’s responsibilities (the “Charter Agreements”).
	 
	 	(4)	 	The Charter Agreements shall, at a minimum, identify a process
for developing and executing the protocol for each TLR9 Agonist Trial and set
forth a trial budget to be paid by Merck, which shall include after [**] the
reimbursement by Merck of Licensor’s internal costs, up to an agreed upon limit
and at an agreed upon rate to be set forth in the budget attached to the
respective Charter Agreement and pre-approved Development Costs in conducting
such trial (each a “Trial Budget”).
	 
	 	(5)	 	Merck shall have responsibility for determining if any Future
Trial is to be conducted and for defining objectives of any Future Trial.
	 
	 	(6)	 	Merck shall seek Licensor’s input on each Future Trial.
	 
	 	(7)	 	If requested by Merck during the Interim Period, Licensor
agrees to initiate and conduct the [**] Trial during the Interim Period,
subject to the terms of a mutually agreed Charter Agreement, unless Licensor,
in its reasonable discretion, determines that it is unable to conduct such
trial, wherein such determination takes into account [**] under the relevant
Charter Agreement.
	 
	 	(8)	 	For each Future Trial [**] that Merck desires to initiate
during the Interim Period, Licensor agrees to initiate and conduct such Future
Trial during the Interim Period, subject to the terms of a mutually agreed
Charter Agreement, unless Licensor, in its sole discretion, determines that it
is unable to conduct such trial. Such inability determination shall take into
[**] under the relevant Charter Agreement.
	 
	 	(9)	 	Licensor shall have the right to take, at its sole discretion
after appropriate discussions with Merck under the Charter Agreements, any
actions it reasonably deems necessary or desirable to fulfill the regulatory
requirements appropriate to the role of Sponsor for any or all TLR9 Agonist
Trials.
	 
	 	(10)	 	For the avoidance of doubt, if the Initiation of a Future Trial
by Idera would qualify as a milestone payment triggering event as set forth in
Section 5.2 if

					
	 	 	 	 	 
	License Agreement Amendment
	 	Page 2 of 10
	 	Confidential

 

 

Execution Version

	 	 	 	such Initiation had been undertaken by Merck, such milestone shall be
considered achieved as if Merck achieved such milestone and all payments
resulting therefrom shall be due and payable by Merck to Idera according to
the Agreement.
	 
	 	(11)	 	Notwithstanding Section 3.4(b)(10), the Parties agree that the
Initiation of the [**] Trial shall in no event be considered [**].
	 
	 	(12)	 	Licensor’s acts pursuant to the provisions of this Section
3.4(b) shall not be considered a breach of Section 2.6 or Section 3.1.
	 
	 	(13)	 	Merck’s acts pursuant to the provisions of this Section 3.4(b),
as well as the fact that Merck [**], shall not be considered a breach of
Section 3.2 or Section 3.9.
	 
	 	(14)	 	Licensor has entered into a contract with [**] pursuant to
which [**] is to perform certain labeling, storage, packing and distribution
activities related to [**] on behalf of Licensor. During the Interim Period
and in accordance with Merck’s direction, Licensor shall manage the labeling,
packing and distribution of [**] vials of [**] via [**] for purposes of (i)
completion of transfer of the manufacturing technology as provided for under
this License Agreement, (ii) the On-Going Trials and (iii) any Future Trials.
Licensor shall not be responsible for manufacturing any amounts of [**] in
addition to the [**] vials referenced in this clause (14). To the extent that
Licensor follows the direction given by Merck pursuant to this clause (14),
Merck shall be accountable for the allocation of such vials to the transfer of
the manufacturing technology activities, the On-Going Trials and any Future
Trials
	 
	 	(15)	 	With respect to each TLR9 Agonist Trial, Licensor shall own the
corresponding clinical data generated by that Trial (the “Clinical Data”) until
such time as Merck shall [**]. Merck shall have a fully paid, royalty free,
exclusive license to use, disclose and copy the Clinical Data related to such
Trial to bring about the purposes of this License Agreement, the Charter
Agreements and the filing of the Merck TLR9 Agonists IND. Licensor shall retain
the right to use, disclose and copy (i) any and all Clinical Data during the
Interim Period as necessary to comply with applicable laws, rules and
regulations and to publish in accordance with Section 7.2 of the License
Agreement, (ii) any safety data in connection with contractual
pharmacovigilance obligations to third parties and (iii) the final study report
for [**] to the extent necessary to comply with [**]. In connection with the
foregoing and to the fullest extent permitted by law, Licensor shall authorize
any contract research organization, data management company or central
laboratory providing services in respect of a TLR9 Agonist Trial to
concurrently disclose the related Clinical Data to Merck or Merck’s designee.
In respect of Clinical Data for a TLR9 Agonist Trial generated by a Third-Party
vendor other than a contracts research organization, data management company or
central laboratory, Licensor shall promptly and timely disclose Clinical Data
to Merck after receipt thereof from such Third-Party vendor. Without additional
action or payment of an additional fee, ownership of the Clinical Data will
transfer from

					
	 	 	 	 	 
	License Agreement Amendment
	 	Page 3 of 10
	 	Confidential

 

 

Execution Version

	 	 	 	Licensor to Merck at the end of the Interim Period; provided, that Licensor
shall have a fully paid, royalty free, non-exclusive license to use and
disclose (i) the Clinical Data for purposes of any required regulatory
filings in connection with a TLR9 Agonist Trial or to respond to any
regulatory inquiries related to the period when Licensor was Sponsor of such
Trial and (ii) any safety data that are generated from a TLR9 Agonist Trial
for Licensor’s and its collaborators’ and their affiliates’ regulatory
purposes.
	 
	 	(16)	 	Licensor agrees that during such time that Licensor is owner of
any Clinical Data, such ownership rights shall be subject to and to the extent
applicable, limited by, the terms of this License Agreement, including Section
7.2(c).
	 
	 	(17)	 	Strategic Development Committee.

	 	(i)	 	The Parties shall establish a committee for the
purpose of reviewing and exchanging information regarding the general
direction and progress of the TLR9 Agonist Trials during the Interim
Period (the “Strategic Development Committee” or “SDC”). Each Party
shall designate two (2) individuals to be its authorized
representatives on the Strategic Development Committee (each a “SDC
Representative”). Merck shall also appoint one of the SDC
Representatives it has designated as the chair of the Strategic
Development Committee (the “SDC Chair”). The initial SDC
Representatives and chairperson are set forth on Schedule 3.4(b).
Each Party may change its SDC Representatives, or Merck may change its
designee for the SDC Chair, as the case may be, from time to time,
effective upon notice to the other Party of such change. Additional
representatives or consultants may from time to time, by mutual consent
of the Parties, be invited to attend SDC meetings. Except as expressly
set forth in clauses (ii) and (iii) below, the SDC shall function
solely as a forum for reviewing and exchanging information regarding
the progress and overall direction of the TLR9 Agonist Trials and not
as a decision-making body. The SDC shall meet in accordance with a
schedule established by the SDC Chair (taking in consideration the
availability of the SDC Representatives), but no less frequently than
once a month during the Interim Period and as needed to address an
Unresolved Issue as provided under clauses (ii) and (iii) below. Such
meetings will occur via teleconference, videoconference or in-person,
as determined by the SDC Chair. For an in-person SDC meeting held more
than fifty (50) miles outside of Boston, Massachusetts, Merck will
reimburse Licensor, in accordance with and subject to its corporate
travel and expense policies, for the reasonable travel expenses
incurred by Licensor’s SDC Representatives in connection with their
attendance of such meeting outside of Boston. The SDC Chair shall
ensure that relevant results of such SDC meetings are recorded and
approved by all SDC Representatives.

					
	 	 	 	 	 
	License Agreement Amendment
	 	Page 4 of 10
	 	Confidential

 

 

Execution Version

	 	(ii)	 	A specific study team comprised of
representatives designated by both Licensor and Merck will be formed in
respect of each TLR9 Agonist Trial (each a “Study Team”). With respect
to each TLR9 Agonist Trial, the applicable Study Team will be charged
with certain decision-making responsibilities related to that Trial as
set forth in the Trial’s Charter Agreement. Each Charter Agreement
will set out the procedures pursuant to which an unresolved issue,
requiring the unanimous consent of the Study Team members, may be
brought before the Strategic Development Committee (each an “Unresolved
Issue”). In the event that the SDC Representatives receive written
notice of an Unresolved Issue together with a summary thereof and the
action to be decided upon (an “Issue Summary”), the SDC Representatives
shall discuss the Unresolved Issue and shall meet with respect thereto
if one or more of them believes a meeting or meetings to be useful. If
the SDC Representatives do not resolve the matter within thirty (30)
days following receipt by them of the Issue Summary (or such lesser or
longer period as they may agree is appropriate for their discussions),
then the SDC Chair shall, after due and reasonable consideration and
subject to clause (iii) below, make the final decision regarding the
Unresolved Issue unless such issue is a Safety Issue as defined below.
In that case, Licensor’s SDC Representatives shall, after due and
reasonable consideration, including consultation with the safety team
representatives assigned to the relevant Study, make the final decision
regarding such Safety Issue. Licensor’s SDC Representatives shall
promptly inform the SDC Chair in writing of any final decisions
regarding Safety Issues reached in accordance with this clause (ii).
For purposes of this clause (ii), a Safety Issue is (A) any strategy
decision regarding a TLR9 Agonist Trial (including a decision to
terminate any such Trial) or material change to a TLR9 Agonist Trial
protocol that is under consideration which arises from safety findings
or other safety matters related to a Compound or (B) any change to a
TLR9 Agonist Trial protocol that could reasonably be expected to
significantly alter the foreseeable risks or discomforts to a TLR9
Agonist Trial subject. The SDC Chair shall provide the applicable
Study Team written notice, with a copy to all other SDC
Representatives, of any final decision regarding an Unresolved Issue
reached by the Strategic Development Committee pursuant to this clause
(ii).

	 	(iii)	 	Notwithstanding any of the foregoing, the SDC
Chair shall not make a final determination regarding an Unresolved
Issue the implementation of which could reasonably be expected to have
a material adverse effect on Licensor due to any liabilities or
obligations under laws, rules or regulations applicable to Licensor as
Sponsor of the relevant TLR9 Agonist Trial (a “Sponsor

					
	 	 	 	 	 
	License Agreement Amendment
	 	Page 5 of 10
	 	Confidential

 

 

Execution Version

	 	 	 	MAE”). For purposes of the foregoing, (A) during the course of
Strategic Development Committee discussions regarding an Unresolved
Issue, each of the Parties should endeavor to discuss specific
proposals to resolve the relevant issue and Licensor shall endeavor
in good faith to identify any aspect of a proposal the implementation
of which could reasonably be expected to result in a Sponsor MAE and
(B) the Merck SDC Representatives shall provide Licensor written
notice of any proposed final determination (“Proposed Final
Determination”) to be made hereunder (“Final Determination Notice”)
before its implementation. A Licensor’s SDC Representative shall
notify the Merck SDC Representatives in writing within five (5)
Business Days of receipt of a Final Determination Notice if in
Licensor’s reasonable opinion, a Proposed Final Determination could
result in a Sponsor MAE. In the absence of any such notice within
such five Business Day period, the Proposed Final Determination shall
become final and shall be implemented by written notification to the
applicable Study Team. In the event a Licensor’s SDC Representative
delivers such notice with respect to a Proposed Final Determination,
Merck shall not take any steps to implement the Proposed Final
Determination and may submit to Licensor SDC Representatives another
Proposed Final Determination that will be subject to this clause
(iii).

3. Section 9.1, Indemnification by Merck, shall be amended and restated in its entirety as
follows:

9.1 Indemnification by Merck. Merck shall indemnify, defend and hold Licensor and its
Affiliates and each of the respective employees, officers, directors and agents (the
“Licensor Indemnitees”) harmless from and against any and all liability, damage, loss,
cost or expense (including reasonable attorneys’ fees) to the extent arising out of
Third Party claims or suits related to (a) Merck’s acts or omissions, during the Interim
Period, in connection with the On-Going Trials or the Future Trials, (b) the
Development, manufacture, use or Commercialization of a Compound, Follow-On Compound or
Licensed Product by or on behalf of Merck, its Affiliates or Sublicensees, (c) the use,
handling or storage of any Licensor Materials by or on behalf of Merck, its Affiliates
or Sublicensees, (d) Merck’s performance of its obligations under this Agreement, (e)
breach by Merck of its representations, warranties or covenants set forth in this
Agreement; provided, however, that Merck’s obligations pursuant to this Section 9.1
shall not apply to the extent such claims or suits (i) result from the negligence or
willful misconduct of any of the Licensor Indemnitees or (ii) arise out of a breach by
Licensor of its representations, warranties or covenants set forth in this Agreement.

					
	 	 	 	 	 
	License Agreement Amendment
	 	Page 6 of 10
	 	Confidential

 

 

Execution Version

4. Section 9.2, Indemnification by Licensor, shall be amended and restated in its entirety
as follows:

9.2. Indemnification by Licensor. Licensor shall indemnify, defend and hold Merck
and its Affiliates and each of their respective agents, employees, officers and
directors (the “Merck Indemnitees”) harmless from and against any and all liability,
damage, loss, cost or expense (including reasonable attorney’s fees) to the extent
arising out of Third Party claims or suits related to (a) Licensor’s acts or omissions,
subject to the delegation of responsibilities to Merck or its Affiliates under any
applicable Charter Agreement, in conducting the On-Going Trials or the Future Trials
prior to and during the Interim Period, (b) the Development, manufacture, use or
Commercialization of Compounds or Follow-On Compounds by or on behalf of Licensor, its
Affiliates or licensees, (c) Licensor’s performance of its obligations under this
Agreement, (d) breach by Licensor of its representations, warranties or covenants set
forth in this Agreement, or (e) the matters set forth in paragraph 1 of the letter from Licensor to Merck dated December 17, 2007; provided, however, that
Licensor’s obligations pursuant to this Section 9.2 shall not apply to the extent such
claims or suits (i) result from the negligence or willful misconduct of any of the Merck
Indemnitees or (ii) arise out of a breach by Merck of its representations, warranties or
covenants set forth in this Agreement.

5. Section 9.5, Insurance, shall be amended and restated in its entirety as follows:

9.5 Insurance. During the Interim Period and with respect to each TLR9 Agonist Trial,
Licensor shall obtain and maintain, occurrence-form, product liability insurance with a
clinical trials endorsement, or clinical trials insurance, in an amount that is agreed
by Licensor and Merck as reasonable and customary in the United States pharmaceutical
and biotechnology industries for companies engaged in comparable activities. Merck
agrees to reimburse Licensor for the cost incurred by Licensor in obtaining such
insurance, up to the amount set forth as insurance expense payable or reimbursable by
Merck set forth in the applicable Trial Budget. After the Interim Period, until
expiration or termination of the Term, each Party shall bear its own costs of obtaining
and maintaining occurrence-form, product liability insurance with a clinical trials
endorsement, or clinical trials insurance (including self-insured arrangements), in
amounts that are reasonable and customary in the United States pharmaceutical and
biotechnology industry for companies engaged in comparable activities. It is understood
and agreed that this insurance shall not be construed to limit either Party’s liability
with respect to its indemnification obligations hereunder. Each Party will, except to
the extent self insured as permitted under this Section 9.5, provide to the other Party
upon request a certificate evidencing the insurance such Party is required to obtain and
keep in force under this Section 9.5. To the extent possible under each Party’s
respective insurance plans, each Party will notify the other Party at least thirty (30)
days prior to the expiration or cancellation of such insurance, or any reduction in
coverage thereunder.

6. The Schedules to the License Agreement are hereby amended with the addition of Schedule
3.4(b) attached hereto.

					
	 	 	 	 	 
	License Agreement Amendment
	 	Page 7 of 10
	 	Confidential

 

 

Execution Version

7. All other terms and conditions of the License Agreement shall remain in full force and
effect.

[SIGNATURE PAGE FOLLOWS]

					
	 	 	 	 	 
	License Agreement Amendment
	 	Page 8 of 10
	 	Confidential

 

 

Execution Version

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Date.

	 	 	 	 	 
	Idera Pharmaceuticals, Inc.	 	 
	 
	 	 	 	 
	By:

	 	/s/ Louis Arcudi, III
	 	 
	 

	 	 	 	 
	Name:

	 	Louis Arcudi, III	 	 
	Title:

	 	Chief Financial Officer	 	 
	Date:

	 	11 Feb 2009	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Merck KGaA	 	 
	 
	 	 	 	 
	By:

	 	/s/ Dr. Claudia [illegible]	 	 
	 

	 	 	 	 
	Name:

	 	Dr. Claudia [illegible]	 	 
	Title:
	 	 	 	 
	Date:

	 	13 Feb 2009	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	By:

	 	/s/ Jens Eckhardt	 	 
	 

	 	 	 	 
	Name:

	 	Jens Eckhardt	 	 
	Title:

	 	Legal Counsel	 	 
	Date:

	 	13 Feb 2009	 	 
	 

	 	 	 	 

					
	 	 	 	 	 
	License Agreement Amendment
	 	Page 9 of 10
	 	Confidential

 

 

Schedule 3.4(b)

Strategic Development Committee Members

Idera SDC Representatives: [**]

Merck SDC Representative: [**]

Merck SDC Representative/SDC Chair: [**]

  

 

	17 December 2007                                         		CONFIDENTIAL	

Jens Eckhardt

Associate General Counsel

Merck Serono Legal Department

MERCK KGaA

Frankfurter Str. 250

D-64293 Darmstadt                                                                  Germany

Dear Jens:

This letter is provided
 for the purpose of formally disclosing certain matters to Merck KGaA (“Merck”) in
 connection with a License Agreement dated December 18, 2007 (the “Agreement”)
by and between Idera Pharmaceuticals, Inc. (“Idera”) and Merck.  This letter constitutes
Confidential Information of Idera under the Agreement.

1. Idera’s U.S.
 Patent Application Serial No. 10/846,167 (‘167 application), filed 14 May 2004,
 names only Idera Pharmaceuticals employees as inventors.  Idera’s outside patent
counsel performed an inventorship determination at the time of filing the ‘167
application.  Idera has reviewed this inventorship determination in light of recent
communications from the University [**] that suggested one
of [**] employees may be an inventor on the ‘167
application.  Based upon these communications, no change has
been made to the inventorship of the ‘167 application.  Idera
will use Commercially Reasonable Efforts to contest all claims raised
by [**] or the said employee of [**] to the ‘167 application and/or any
patent rights corresponding thereto (such as PCT/US2004/015313, published
 as WO 2004/103301, and all patent rights derived therefrom) and bear all costs related thereto.

[**]

Sincerely,

Steven Ritter, Ph.D., J.D.

Intellectual Property Counselexv10w1

Exhibit 10.1

SECOND AMENDMENT

TO FOURTH AMENDED AND RESTATED REVOLVING LOAN AGREEMENT

     This Second Amendment to Fourth Amended and Restated Revolving Loan Agreement (this
“Amendment”) is entered into as of October 6, 2009, by and between ViaSat, Inc., a Delaware
corporation (“Borrower”), each lender party to the Credit Agreement (as defined below)
(collectively, the “Lenders” and individually, a “Lender”) that is a signatory hereto, UNION BANK,
N.A., as Administrative Agent (in such capacity, “Administrative Agent”), BANK OF AMERICA, N.A., as
Syndication Agent, JPMORGAN CHASE BANK, N.A., as Documentation Agent, BANC OF AMERICA SECURITIES
LLC and UNION BANK, N.A., as Joint Lead Arrangers and Joint Book Runners and UNION BANK, N.A., as
Collateral Agent (in such capacity, “Collateral Agent;” collectively, the “Agents”) and WELLS FARGO
BANK, NATIONAL ASSOCIATION (“New Lender”).

RECITALS

     Borrower, Agents and the Lenders are parties to that certain Fourth Amended and Restated
Revolving Loan Agreement dated as of July 1, 2009 (as amended from time to time, including by that
certain First Amendment to Fourth Amended and Restated Revolving Loan Agreement dated as of
September 30, 2009, collectively, the “Credit Agreement”). New Lender wishes to become a Lender
under the Credit Agreement, and the parties desire to so amend the Credit Agreement, in accordance
with the terms of this Amendment. Unless otherwise defined, all initially capitalized terms in
this Amendment shall be as defined in the Credit Agreement.

     NOW, THEREFORE, the parties agree as follows:

     1. New Lender hereby is added to the Credit Agreement as “Co-Agent” and as a Lender (provided
that, the title of “Co-Agent” shall not connote a co-agency role as Administrative Agent or
Collateral Agent). References in the Loan Documents to “Agents” shall hereby include New Lender in
its capacity as Co-Agent. References in the Loan Documents to “Lender” or “Lenders” shall hereby
mean and include New Lender. New Lender shall be deemed to be a Lender under the Credit Agreement
for all intents and purposes. All loans made by New Lender under the Credit Agreement shall be
“Loans” under, and as defined in, the Credit Agreement.

     2. New Lender hereby has all of the rights and obligations of a “Lender” under the Loan
Documents. New Lender hereby (x) agrees to be bound by all of the terms and conditions of the
Credit Agreement and (y) appoints and authorizes the Administrative Agent and the Collateral Agent
to take such actions on New Lender’s behalf and to exercise such powers as delegated to the
Administrative Agent and the Collateral Agent, respectively, under the Loan Documents, subject to
all the terms and conditions of the Loan Documents, including Article 10 of the Credit Agreement.

     3. Borrower, Agents and the Lenders hereby agree to increase the Commitment, and the Lenders’
respective Pro Rata Shares, in accordance with the terms of Section 2.8 of the Credit
Agreement (as in effect prior to the date of this Amendment; compliance with which hereby is
acknowledged by Administrative Agent), and in the amounts and percentages set forth in Schedule
1.1 to the Credit Agreement, as amended hereby. Borrower, Agents and the Lenders hereby agree
to waive the requirement under Section 2.8(c) of the Credit Agreement that New Lender
execute and deliver to Administrative Agent and Borrower a Commitment Assignment and Acceptance.

     4. The following defined term hereby is amended and restated in Section 1.1 of the
Credit Agreement to read as follows:

     “Commitment” means, subject to Sections 2.5 and 2.8, $210,000,000.
The respective Pro Rata Shares of the Lenders with respect to the Commitment are set forth in
Schedule 1.1.”

1

 

     5. The first sentence of Section 2.8(a) of the Credit Agreement hereby is amended and
restated in its entirety to read as follows:

          “(a) If no Default or Event of Default shall have occurred and be continuing, Borrower may at
any time prior to the Revolving Loan Maturity Date request no more than one (1) increase of the
Commitment by notice to the Administrative Agent in writing of the amount of such proposed increase
(such notice, a “Commitment Increase Notice”); provided, however, that the aggregate amount
of the increase in the Commitment shall not exceed $15,000,000 and shall be in the minimum amount
of $10,000,000.”

     6. Schedule 1.1 to the Credit Agreement hereby is replaced in its entirety with
Schedule 1.1 attached hereto.

     7. No course of dealing on the part of Lenders, Agents or their officers, nor any failure or
delay in the exercise of any right by any Agent or any Lender, shall operate as a waiver thereof,
and any single or partial exercise of any such right shall not preclude any later exercise of any
such right. Agents’ or Lenders’ failure at any time to require strict performance by Borrower of
any provision of any Loan Document shall not affect any right of Lenders or Agents thereafter to
demand strict compliance and performance. Any suspension or waiver of a right must be in writing
signed by an officer of Administrative Agent, in accordance with the terms of the Credit Agreement.

     8. The Credit Agreement, as amended hereby, shall be and remain in full force and effect in
accordance with its respective terms and hereby is ratified and confirmed in all respects. Except
as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not
operate as a waiver of, or as an amendment of, any right, power, or remedy of Agents or Lenders
under the Credit Agreement, as in effect prior to the date hereof.

     9. All Representations and Warranties contained in the Credit Agreement or in any other
document or documents relating thereto shall survive the execution and delivery of this Amendment.
The Borrower is not aware of any events which now constitute, or with the passage of time or the
giving of notice, or both, would constitute, an Event of Default under the Credit Agreement.

     10. As a condition to the effectiveness of this Amendment, Administrative Agent and the
Requisite Lenders (and in the case of (b), below, JPMorgan Chase Bank, N.A. (“JPMorgan”) and New
Lender) shall have received, in form and substance reasonably satisfactory to Administrative Agent
and the Requisite Lenders (and in the case of (b), below, JPMorgan and New Lender), the following:

               (a) this Amendment, duly executed by Borrower, Collateral Agent, each of the other Agents, the
Requisite Lenders and New Lender;

               (b) a Revolving Note (the “Replacement Note”) executed by Borrower in favor of JPMorgan in a
principal amount equal to that JPMorgan’s Pro Rata Share of the Commitment, and a Revolving Note
executed by Borrower in favor of New Lender in a principal amount equal to New Lender’s Pro Rata
Share of the Commitment;

               (c) an Affirmation of Subsidiary Guaranty and Security Agreement, duly executed by each
Guarantor;

               (d) Resolutions of the Board of Directors of Borrower authorizing the execution, delivery and
performance of this Amendment, with an incumbency certificate; each in form and content reasonably
acceptable to Administrative Agent;

               (e) a certificate signed by a Responsible Official of Borrower certifying that the condition
specified in Section 8.1(e) of the Credit Agreement is true and correct as of the date hereof;

2

 

               (f) all reasonable attorneys’ fees and costs incurred by Agents’ counsel through the date of
this Amendment, which may be debited from any of Borrower’s accounts (following Borrower’s
authorization of such fees and costs); and

               (g) such other documents, and completion of such other matters, as Administrative Agent or any
Lender proposing to sign this Amendment may reasonably deem necessary or appropriate.

     11. Upon receipt of the Replacement Note, JPMorgan shall mark the previously issued Revolving
Note “cancelled” and return such Note to Borrower.

     12. The Governing law and venue provisions of Section 11.17 of the Credit Agreement are
incorporated herein by this reference mutatis mutandis. This Amendment may be executed in two or
more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one instrument. Delivery of an executed counterpart hereof by facsimile transmission
shall be effective as delivery of a manually executed counterpart. Except as amended hereby, all
of the provisions of the Credit Agreement and the other Loan Documents shall remain unmodified and
in full force and effect except that each reference to the “Credit Agreement”, “Loan Agreement”,
“Agreement”, or words of like import in any Loan Document, shall mean and be a reference to the
Credit Agreement as amended hereby. This Amendment shall be deemed a “Loan Document” as defined in
the Credit Agreement. Each party shall execute and deliver such further documents, and perform
such further acts, as may be reasonably necessary to achieve the intent of the parties as expressed
in this Amendment.

[Balance of Page Intentionally Left Blank]

3

 

     IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above
written.

	 	 	 	 	 
	 	VIASAT, INC.

 	 
	 	By:  	/s/ Keven K. Lippert
 	 
	 	 	Keven K. Lippert 	 
	 	 	VP, General Counsel and Secretary 	 
	 
	 	Address:

ViaSat, Inc.

6155 El Camino Real

Carlsbad, California 92009

Attn: Ronald G. Wangerin

Chief Financial Officer

Telecopier: (760) 929-3926

Telephone: (760) 476-2200

 	 
	 	 	 
	 	 	 
	 	 	 
	 
	 	UNION BANK, N.A.,

as Administrative Agent

 	 
	 	By:  	/s/ Mark Adelman
 	 
	 	 	Mark Adelman 	 
	 	 	Vice President 	 
	 
	 	Address:

UNION BANK, N.A.

San Diego Commercial Banking Office

530 “B” Street, 4th Floor, S-420

San Diego, California 92101-4407

Attn: Mark Adelman

Telecopier: (619) 230-3766

Telephone: (619) 230-3516

 	 
	 	 	 
	 	 	 
	 	 	 
	 

[Signature Page to Second Amendment to

Fourth Amended and Restated Revolving Loan Agreement]

[Signatures Continued Next Page]

 

 

	 	 	 	 	 
	 	UNION BANK, N.A.,

as Collateral Agent

 	 
	 	By:  	/s/ Mark Adelman
 	 
	 	 	Mark Adelman 	 
	 	 	Vice President 	 
	 
	 	Address:

UNION BANK, N.A.

San Diego Commercial Banking Office

530 “B” Street, 4th Floor, S-420

San Diego, California 92101-4407

Attn: Mark Adelman

Telecopier: (619) 230-3766

Telephone: (619) 230-3516

 	 
	 	 	 
	 	 	 
	 	 	 
	 

	 	 	 	 	 
	 	UNION BANK, N.A.,

as a Lender and Swing Line Lender

 	 
	 	By:  	/s/ Mark Adelman
 	 
	 	 	Mark Adelman 	 
	 	 	Vice President 	 
	 
	 	Address:

UNION BANK, N.A.

San Diego Commercial Banking Office

530 “B” Street, 4th Floor, S-420

San Diego, California 92101-4407

Attn: Mark Adelman

Telecopier: (619) 230-3766

Telephone: (619) 230-3516

 	 
	 	 	 
	 	 	 
	 	 	 
	 

[Signature Page to Second Amendment to

Fourth Amended and Restated Revolving Loan Agreement]

[Signatures Continued Next Page]

 

 

	 	 	 	 	 
	 	BANK OF AMERICA, N.A.,

as a Lender

 	 
	 	By:  	                       /s/ Karin S. Barnes
 	 
	 	 	Name:  	Karin S. Barnes 	 
	 	 	 	Senior Vice President 	 
	 
	 	Address:

Bank of America, N.A.

450 B Street, Suite 1500

San Diego, CA 92101

Attn: Karin S. Barnes

       
Senior Vice President

 	 
	 	 	 
	 	 	 
	 	 	 
	 

[Signature Page to Second Amendment to

Fourth Amended and Restated Revolving Loan Agreement]

[Signatures Continued Next Page]

 

 

	 	 	 	 	 
	 	JPMORGAN CHASE BANK, N.A.,

as a Lender

 	 
	 	By:  	/s/ Anna C. Ruiz
 	 
	 	 	Name:  	Anna C. Ruiz 	 
	 	 	Vice President 	 
	 
	 	Address:

JPMORGAN CHASE BANK, N.A.

650 Town Center Drive, Suite 1000

Costa Mesa, CA 92626

Attn: Anna C. Ruiz

Vice President

 	 

[Signature Page to Second Amendment to

Fourth Amended and Restated Revolving Loan Agreement]

[Signatures Continued Next Page]

 

 

	 	 	 	 	 
	 	BANK OF THE WEST,

as a Lender

 	 
	 	By:  	/s/ Ed Ong
 	 
	 	 	Name:  	Ed Ong 	 
	 	 	Vice President 	 
	 

Address:

BANK OF THE WEST

1280 4th Ave.

San Diego, CA 92101

Attn: Ed Ong

Vice President

[Signature Page to Second Amendment to

Fourth Amended and Restated Revolving Loan Agreement]

[Signatures Continued Next Page]

 

 

	 	 	 	 	 
	 	COMERICA BANK,

as a Lender

 	 
	 	By:  	/s/ Steve D. Clear
 	 
	 	 	Name:  	Steve D. Clear 	 
	 	 	Vice President 	 
	 

Address:

COMERICA BANK

611 Anton Blvd., 4th Floor M/C 4462

Costa Mesa, CA 92626

Attn: Steve D. Clear

Vice President

[Signature Page to Second Amendment to

Fourth Amended and Restated Revolving Loan Agreement]

[Signatures Continued Next Page]

 

 

	 	 	 	 	 
	 	CALIFORNIA BANK & TRUST,

as a Lender

 	 
	 	By:  	/s/ Steve DeLong
 	 
	 	 	Name:  	Steve DeLong 	 
	 	 	 	Senior Vice President 	 
	 

Address:

CALIFORNIA BANK & TRUST

4230 La Jolla Village Drive, Suite 100

San Diego, CA 92122

Attn: Steve DeLong

Senior Vice President

[Signature Page to Second Amendment to

Fourth Amended and Restated Revolving Loan Agreement]

[Signatures Continued Next Page]

 

 

	 	 	 	 	 
	 	WELLS FARGO BANK, NATIONAL ASSOCIATION,

as a Lender

 	 
	 	By:  	/s/ Donald S. Green
 	 
	 	 	Name:  	Donald S. Green 	 
	 	 	Vice President 	 
	 

Address:

WELLS FARGO BANK, NATIONAL ASSOCIATION

401 B St., Suite 2201

San Diego, CA 92101

Attn: Donald S. Green

Vice President

[Signature Page to Second Amendment to

Fourth Amended and Restated Revolving Loan Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]